Please assess the completion status of the following clinical trial:

Trial Title: Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for TALC and BASALT Studies:~* Clinical history consistent with asthma~* Forced expiratory volume in one second (FEV1) greater than 40% of predicted value~* Asthma confirmed by one of the following two criteria:~  1. Beta-agonist reversibility to 4 puffs albuterol of at least 12% OR~ 2. Methacholine provocative concentration at 20% (PC20) of 8 milligrams per milliliter (mg/mL) or less when not on an inhaled corticosteroid (ICS), or 16 mg/mL or less when on an ICS~* Need for daily controller therapy (i.e., ICS, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following criteria:~  1. Received prescription for or used asthma controller within the 12 months prior to study entry OR~ 2. Experienced symptoms for more than twice a week and not on asthma controller~* If on inhaled steroids (any drug at any dose not exceeding the equivalent of 1000 micrograms (mcg) of fluticasone daily), participant must have been on a stable dose for at least 2 weeks prior to study entry~* Non-smoker (i.e., total lifetime smoking history less than 10 pack-years; no smoking for at least 1 year prior to study entry)~* Willing to use an effective form of birth control throughout the study~Inclusion Criteria for TALC Study:~* Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using electronic peak flow meter (EPFM) and to complete the study diary correctly at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period~* Adherence with study medication dosing at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period~* No asthma exacerbation requiring use of oral corticosteroids or additional asthma medications (including an increased dose of ICS) during the run-in period~* FEV1 greater than 40% of the predicted value~Exclusion Criteria for BASALT and TALC Studies:~* Lung disease other than asthma, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis~* Established or suspected diagnosis of vocal cord dysfunction~* Significant medical illness other than asthma~* History of respiratory tract infection within the 4 weeks prior to study entry~* History of a significant asthma exacerbation within the 4 weeks prior to study entry~* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the 5 years prior to study entry~* Hyposensitization therapy other than an established maintenance regimen~* Inability to coordinate use of the delivery devices used in the study, based on the opinion of the investigator or clinical coordinator~* Pregnant~Exclusion Criteria for TALC Study:~* Inability to coordinate use of the medication delivery devices used in the study, based on the opinion of the investigator or clinical coordinator~* Presence at Week 4 of the run-in period of any of the exclusion criteria stipulated for Week 0 of the run-in period (Note: Respiratory tract infections that do not cause the participant to meet exacerbation criteria are not considered exclusionary.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tio + 1xICS || LABA + 1xICS || 2xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
- TIO + 1xICS || 2xICS || LABA + 1xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
- LABA + 1xICS || Tio + 1xICS || 2xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
- LABA + 1xICS || 2xICS || Tio + 1xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
- 2xICS || Tio + 1xICS| || LABA + 1xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).
- 2xICS || LABA + 1xICS || Tio + 1xICS (Type: EXPERIMENTAL): Participants will take part in three 16-week treatment periods, which will occur in the following order:~* beclomethasone dipropionate 160 mcg twice daily (2xICS)~* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS).

Based on this trial design, predict the completion outcome and termination type (if applicable).